CMS on Thursday (July 14) issued guidelines aimed at helping drug makers negotiate value-based purchasing contracts with plans and state Medicaid agencies, but a lobbyist for health plans says the document doesn't do much to clear up uncertainties over how those contracts affect Medicaid best prices for drugs and continues to shoehorn value-based purchasing agreements into the construct of supplemental Medicaid drug rebates. The Medicaid best-price policy is commonly cited as an obstacle to outcomes-based contracts, which CMS calls...